文献速递炎症性肠病

英夫利昔单抗累积暴露而非谷浓度与感染率相关

Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-03-19

该研究纳入209例接受英夫利昔单抗维持治疗的炎症性肠病患者,通过药代动力学模型估算6个月内累积暴露(ΣAUC)。多因素分析显示,吸烟、IBD发作和高ΣAUC(>3234 mg·d/L)与感染独立相关,而谷浓度单独与感染无关。

要点

  • 英夫利昔单抗累积暴露(ΣAUC)高与感染风险增加独立相关。
  • 谷浓度单独与感染无显著关联。
  • 吸烟和IBD发作也是感染的独立危险因素。

核心结论

  • 英夫利昔单抗累积暴露增加与感染风险独立相关,而谷浓度单独与感染无关。

研究设计与样本

  • 研究纳入209例接受英夫利昔单抗维持治疗的IBD患者(102例男性,平均年龄39岁,159例克罗恩病,54例联合治疗),收集640次输注访视数据,基于药代动力学模型估算AUC和6个月ΣAUC。

主要发现

  • 640次输注访视共收集215次感染,123例患者(59%)至少发生1次感染。
  • 英夫利昔单抗谷浓度单独与感染无关联。

关键数值与推荐

  • 平均英夫利昔单抗谷浓度为5.46 mg/L,平均ΣAUC为3938±1427 mg·d/L。

临床怎么用

  • 在英夫利昔单抗治疗IBD患者中,评估累积药物暴露(ΣAUC)可能有助于识别感染高风险患者。
  • 吸烟和IBD发作也应作为感染风险评估的因素。
  • 谷浓度监测单独可能不足以预测感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Infliximab increases the risk of infection in patients with inflammatory bowel diseases (IBD), but there is controversy over the relationship between drug concentration and infections. We aimed to assess factors associated with infection in infliximab-treated patients, including pharmacokinetic features. METHODS: We collected data from 209 patients with IBD (102 men; mean age, 39 y; 159 with Crohn's disease; 54 received combination therapy) who received an infliximab maintenance regimen from November 2016 through April 2017 in France. Data were collected from each infusion visit (total of 640 infusions). Infliximab exposure was estimated based on the area under the curve (AUC) of drug concentration in pharmacokinetic models; individual exposures over the 6-month period were estimated based on the sum of the AUC (ΣAUC). RESULTS: The mean infliximab trough level was 5.46 mg/L, and the mean ΣAUC was 3938 ± 1427 mg.d/L. A total of 215 infections were collected from the 640 infusion visits; 123 patients (59%) had at least 1 infection. Factors independently associated with infection after multivariate analysis were smoking (odds ratio [OR], 2.05; P = .046), IBD flare (OR, 2.71; P = .006), and a high ΣAUC of infliximab (above 3234 mg x d/L) (OR, 2.02; P = .02). The ΣAUC was higher in patients with an occurrence of infection (P = .04) and correlated with the number of infections (P = .04). Trough concentration of infliximab alone was not associated with infection. CONCLUSIONS: Almost two-thirds of patients treated with infliximab developed an infection; risk was individually correlated with cumulative increase in drug exposure, but not infliximab trough level.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Landemaine A, Petitcollin A, Brochard C, et al. Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. Clin Gastroenterol Hepatol. 2020. PMID: 32200087. doi:10.1016/j.cgh.2020.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。